Stock listing
Frankfurt:6FK Gentian Diagnostics ASA Aktie
German listing (Frankfurt) of Gentian Diagnostics ASA · home listing Oslo:GENT
Follow Gentian Diagnostics ASA into a list and get an email when it puts out news.
Share price · FWB:6FK
€3.63 EUR -0.02 (-0.5%)
Close on Nov 20, 2026
- Day range
- €3.63 – €3.63 EURNov 20, 2026
- Market cap
- €56.11M EURAt the close on Nov 20, 2026 · price × 15.46M shares outstanding
- 52-week range
- €3.07 – €5.19 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €0 EURMedian day 0 shares · 57 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Oslo:GENT · Home | 39.60 NOK | +0.40 (+1.0%) | 50,612 | 39.20 | 39.60 | 39.20 | 39.20 | Close on Nov 20, 2026 |
| Frankfurt:6FK | €3.63 EUR | -0.02 (-0.5%) | — | €3.63 | €3.63 | €3.63 | €3.65 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:6FK · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €3.621 | -0.124 | -3.3% | €3.621 | €3.621 | €3.621 | 0 | |
| €3.745 | 0.00 | 0.0% | €3.745 | €3.745 | €3.745 | 0 | |
| €3.745 | -0.049 | -1.3% | €3.745 | €3.745 | €3.745 | 0 | |
| €3.794 | +0.135 | +3.7% | €3.794 | €3.794 | €3.794 | 0 | |
| €3.659 | +0.002 | +0.1% | €3.659 | €3.659 | €3.659 | 0 | |
| €3.657 | -0.119 | -3.2% | €3.657 | €3.657 | €3.657 | 0 | |
| €3.776 | +0.007 | +0.2% | €3.776 | €3.776 | €3.776 | 0 | |
| €3.769 | +0.105 | +2.9% | €3.769 | €3.769 | €3.769 | 0 | |
| €3.664 | -0.114 | -3.0% | €3.664 | €3.664 | €3.664 | 0 | |
| €3.778 | +0.048 | +1.3% | €3.778 | €3.778 | €3.778 | 0 | |
| €3.73 | +0.094 | +2.6% | €3.73 | €3.73 | €3.73 | 0 | |
| €3.636 | -0.093 | -2.5% | €3.636 | €3.636 | €3.636 | 0 | |
| €3.729 | -0.153 | -3.9% | €3.729 | €3.729 | €3.729 | 0 | |
| €3.882 | +0.342 | +9.7% | €3.882 | €3.882 | €3.882 | 0 | |
| €3.54 | +0.074 | +2.1% | €3.54 | €3.54 | €3.54 | 0 | |
| €3.466 | -0.14 | -3.9% | €3.466 | €3.466 | €3.466 | 0 | |
| €3.606 | -0.035 | -1.0% | €3.606 | €3.606 | €3.606 | 0 | |
| €3.641 | +0.079 | +2.2% | €3.641 | €3.641 | €3.641 | 0 | |
| €3.562 | -0.008 | -0.2% | €3.562 | €3.562 | €3.562 | 0 | |
| €3.57 | +0.043 | +1.2% | €3.57 | €3.57 | €3.57 | 0 | |
| €3.527 | -0.031 | -0.9% | €3.527 | €3.527 | €3.527 | 0 | |
| €3.558 | +0.056 | +1.6% | €3.558 | €3.558 | €3.558 | 0 | |
| €3.502 | +0.04 | +1.2% | €3.502 | €3.502 | €3.502 | 0 | |
| €3.462 | -0.089 | -2.5% | €3.462 | €3.462 | €3.462 | 0 | |
| €3.551 | -0.002 | -0.1% | €3.551 | €3.551 | €3.551 | 0 | |
| €3.553 | +0.23 | +6.9% | €3.553 | €3.553 | €3.553 | 0 | |
| €3.323 | -0.067 | -2.0% | €3.323 | €3.323 | €3.323 | 0 | |
| €3.39 | -0.068 | -2.0% | €3.39 | €3.39 | €3.39 | 0 | |
| €3.458 | -0.044 | -1.3% | €3.458 | €3.458 | €3.458 | 0 | |
| €3.502 | +0.063 | +1.8% | €3.502 | €3.502 | €3.502 | 0 | |
| €3.439 | -0.068 | -1.9% | €3.439 | €3.439 | €3.439 | 0 | |
| €3.507 | +0.037 | +1.1% | €3.507 | €3.507 | €3.507 | 0 | |
| €3.47 | -0.09 | -2.5% | €3.47 | €3.47 | €3.47 | 0 | |
| €3.56 | -0.005 | -0.1% | €3.56 | €3.56 | €3.56 | 0 | |
| €3.565 | +0.004 | +0.1% | €3.565 | €3.565 | €3.565 | 0 | |
| €3.561 | -0.028 | -0.8% | €3.561 | €3.561 | €3.561 | 0 | |
| €3.589 | +0.063 | +1.8% | €3.589 | €3.589 | €3.589 | 0 | |
| €3.526 | -0.001 | 0.0% | €3.526 | €3.526 | €3.526 | 0 | |
| €3.527 | -0.043 | -1.2% | €3.527 | €3.527 | €3.527 | 0 | |
| €3.57 | -0.048 | -1.3% | €3.57 | €3.57 | €3.57 | 0 | |
| €3.618 | -0.07 | -1.9% | €3.618 | €3.618 | €3.618 | 0 | |
| €3.688 | +0.03 | +0.8% | €3.688 | €3.688 | €3.688 | 0 | |
| €3.658 | +0.186 | +5.4% | €3.658 | €3.658 | €3.658 | 0 | |
| €3.472 | -0.036 | -1.0% | €3.472 | €3.472 | €3.472 | 0 | |
| €3.508 | -0.027 | -0.8% | €3.508 | €3.508 | €3.508 | 0 | |
| €3.535 | +0.093 | +2.7% | €3.535 | €3.535 | €3.535 | 0 | |
| €3.442 | -0.098 | -2.8% | €3.442 | €3.442 | €3.442 | 0 | |
| €3.54 | -0.009 | -0.3% | €3.54 | €3.54 | €3.54 | 0 | |
| €3.549 | -0.038 | -1.1% | €3.549 | €3.549 | €3.549 | 0 | |
| €3.587 | +0.015 | +0.4% | €3.587 | €3.587 | €3.587 | 0 | |
| €3.572 | -0.004 | -0.1% | €3.572 | €3.572 | €3.572 | 0 | |
| €3.576 | +0.056 | +1.6% | €3.576 | €3.576 | €3.576 | 0 | |
| €3.52 | +0.055 | +1.6% | €3.52 | €3.52 | €3.52 | 0 | |
| €3.465 | -0.039 | -1.1% | €3.465 | €3.465 | €3.465 | 0 | |
| €3.504 | +0.097 | +2.8% | €3.504 | €3.504 | €3.504 | 0 | |
| €3.407 | -0.083 | -2.4% | €3.407 | €3.407 | €3.407 | 0 | |
| €3.49 | +0.05 | +1.5% | €3.49 | €3.49 | €3.49 | 0 |
- Ticker
- Frankfurt:6FK
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Jul 9, 2026
Second quarter 2026 report
Latest deck · Oct 20, 2026
Q3 2026 Earnings Presentation
Earnings · 35 slides
Latest news
Second quarter 2026 report
Jul 9, 2026
Closed €3.35 (+8.8%) on Jul 9, 2026
Essange Reagents And Gentian Diagnostics Announce Collaboration Agreement
Jun 24, 2026
Closed €3.13 (-0.7%) on Jun 24, 2026
Join our R&D Team in Gothenburg
May 28, 2026
Closed €3.36 (+2.4%) on May 28, 2026
Gentian Diagnostics: Vatne Capital Reduces Indirect Ownership
May 13, 2026
Closed €3.47 (-3.9%) on May 13, 2026
Serum calprotectin - marker of systemic inflammation and disease activity
May 12, 2026
Closed €3.61 (+2.6%) on May 12, 2026
GENT: Q1 saw stable sales, NT-proBNP project termination, and a focus on new growth opportunities
May 6, 2026
Closed €4.08 (+2.9%) on May 6, 2026
Gentian Diagnostics: Invitation to presentation of first quarter results
Apr 29, 2026
Closed €3.91 (-1.6%) on Apr 29, 2026
Gentian Diagnostics Renews Long-Term Partnership With Bühlmann Laboratories
Apr 20, 2026
Closed €3.95 (+4.6%) on Apr 20, 2026
Gentian Diagnostics ASA - Registration of share capital increase
Apr 10, 2026
Closed €3.65 (+2.1%) on Apr 10, 2026
Calprotectin as a biomarker for immune dysfunction and 28‑day mortality in sepsis
Mar 26, 2026
Closed €3.40 (+1.5%) on Mar 26, 2026
Gentian Diagnostics ASA on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 19 in the last 12 months · 30 in all · newest Jul 9, 2026 · oldest 2024
- Decks
- 32 decks · latest Oct 20, 2026
Where Gentian Diagnostics ASA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Oslo:GENT · Home listing | Oslo | Norway | NOK |
| Stockholm:GENTO | Stockholm | Sweden | NOK |
| LS Exchange:A2DLP7 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2DLP7 | Lang & Schwarz | Germany | EUR |
| Frankfurt:6FK · This page | Frankfurt | Germany | EUR |
| Dusseldorf:6FK | Dusseldorf | Germany | EUR |
| Stuttgart:6FK | Stuttgart | Germany | EUR |
Valuation
EV/sales 2.7× against a median of 3.0×: 6th lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 520.8M NOK
- P/E
- Loss
- EV/sales
- 2.7×
- EV/EBITDA
- 38.0×
- Price/book
- 3.2×
- Gross margin
- 56.8%
- Operating margin
- −1.1%
- Net margin
- −2.6%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Gentian Diagnostics ASA · OSL:GENT | US$62.79M | US$53.42M | n/a | 2.7× | 38.0× | 3.2× | −2.6% | 0.0× | n/a |
| Seer, Inc. · NASDAQ:SEER | US$75.91M | −US$58.25M | n/a | −4.1× | n/a | 0.4× | −450.9% | 0.1× | 1.03 |
| Selvita SA · GPW:SLV | US$75.24M | US$113.4M | n/a | 1.4× | 9.1× | 1.0× | −0.6% | 0.5× | n/a |
| Sera Prognostics, Inc. · NASDAQ:SERA | US$69.65M | US$28.84M | n/a | 300× | n/a | 1.3× | n/a | 0.1× | 0.57 |
| BioPorto A/S · OMXCOP:BIOPOR | US$68.30M | US$58.06M | 53.8× | 10.7× | n/a | 5.7× | 23.3% | 0.1× | n/a |
| Nanoform Finland Oyj · OMXHEX:NANOFH | US$66.63M | US$52.80M | n/a | 11.9× | n/a | 1.7× | −339.1% | 0.2× | n/a |
| Applied BioCode Corp. · TWSE:6598 | US$64.88M | US$49.53M | n/a | 2.5× | n/a | 3.0× | −7.3% | 0.1× | n/a |
| Insight Molecular Diagnostics Inc. · NASDAQ:IMDX | US$64.53M | US$55.70M | n/a | 28.3× | n/a | n/a | n/a | n/a | 1.77 |
| Prestige Biologics Co., Ltd. · KRX:334970 | US$61.06M | US$72.08M | n/a | 3.6× | n/a | 0.9× | −192.1% | 0.2× | n/a |
| Champions Oncology, Inc. · NASDAQ:CSBR | US$60.41M | US$56.05M | n/a | 0.9× | 168× | 15.5× | −1.9% | 0.0× | 0.40 |
| DreamCIS, Inc. · KRX:223250 | US$60.13M | US$33.21M | 246× | 0.6× | 5.4× | 1.1× | 0.4% | 0.0× | n/a |
| Median of the others | US$65.75M | US$54.25M | 150× | 3.0× | 9.1× | 1.3× | −4.6% | 0.1× | 0.80 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 60.00 NOK · Analysts' mean
- EPS, year to Dec 2026
- 1.90 · 1 analyst
- Revenue, year to Dec 2026
- 198M · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Njaal Kind | CFO |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 20, 2026 | −1.8% |
| Q2 2026 | Jul 10, 2026 | −2.8% |
| Q1 2026 | May 7, 2026 | −2.3% |
| Q4 2025 | Feb 12, 2026 | −29.6% |
| Q3 2025 | Oct 24, 2025 | +3.0% |
| Q2 2025 | Jul 11, 2025 | −4.8% |
| Q1 2025 | May 7, 2025 · Before open | +8.1% |
| Q4 2024 | Feb 12, 2025 · Before open | +2.5% |
| Q3 2024 | Oct 31, 2024 | −6.8% |
| Q2 2024 | Aug 29, 2024 · Before open | −0.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 30, 2024 · Before open | +2.5% |
| Q4 2023 | Feb 9, 2024 · Before open | −2.6% |
| Q3 2023 | Oct 26, 2023 | −2.2% |
| Q2 2023 | Aug 24, 2023 | −1.1% |
| Q1 2023 | May 5, 2023 · Before open | 0.0% |
| Q4 2022 | Feb 16, 2023 · Before open | +1.2% |
| Q3 2022 | Oct 27, 2022 · Before open | +4.5% |
| Q2 2022 | Aug 25, 2022 · Before open | +1.6% |
| Q1 2022 | Apr 28, 2022 · Before open | −6.5% |
| Q4 2021 | Feb 17, 2022 · Before open | −9.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 35 slides | Oct 20, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 33 slides | Jul 9, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 35 slides | May 6, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 37 slides | Feb 11, 2026 |
| DNB Nordic Healthcare Conference 2025 | Conference | 24 slides | Nov 25, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 35 slides | Oct 23, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 35 slides | Jul 10, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 35 slides | May 7, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 36 slides | Feb 12, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 33 slides | Oct 31, 2024 |
All 32 decks
Financials
Annual, in NOK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 176.5M | 152.1M | 135.2M | 101.6M | 83.1M | 68.4M | 48.0M | 46.1M | 35.0M | 30.9M |
| Cost of revenue | 78.3M | 69.3M | 70.9M | 52.6M | 43.2M | 32.6M | 25.4M | 6.59M | 5.79M | 7.02M |
| Gross profit | 98.2M | 82.8M | 64.2M | 49.0M | 39.9M | 35.8M | 22.5M | 39.5M | 29.2M | 23.9M |
| Research and development | 23.2M | 21.9M | 36.1M | 24.7M | 26.8M | 26.1M | 19.2M | 3.80M | 3.94M | 2.15M |
| Selling, general and administrative | 54.3M | 21.7M | 25.1M | 46.6M | 38.4M | 56.2M | 49.2M | 18.2M | 5.96M | 16.3M |
| Operating income | 25.5M | 15.7M | -12.8M | -23.2M | -22.8M | -17.8M | -27.2M | -20.7M | -16.2M | -10.1M |
| Depreciation and amortization | 9.12M | 8.96M | 9.57M | 10.2M | 7.35M | 6.63M | 6.13M | 3.90M | 3.02M | 2.30M |
| EBITDA | 34.6M | 24.7M | -3.20M | -13.0M | -15.5M | -11.2M | -21.0M | -16.8M | -13.2M | -7.75M |
| Interest expense | 5.22M | 2.52M | 3.41M | 4.21M | 4.03M | 550.0K | 363.0K | 64.4K | 19.8K | 1.34M |
| Income before tax | 25.7M | 20.1M | -10.4M | -23.6M | -24.8M | -17.5M | -39.8M | -19.7M | -15.1M | -8.93M |
| Income tax | 12.4M | -25.2M | 282.0K | 0 | 0 | -355.0K | 63.0K | 63.7K | 32.9K | 1.13M |
| Net income | 13.3M | 45.3M | 45.3M | 45.3M | -24.8M | -17.1M | -39.9M | -19.8M | -15.2M | -8.93M |
| Earnings per share, basic | 86.00 | 294.00 | -0.69 | -1.53 | -1.61 | -1.11 | -2.59 | -1.29 | -1.08 | -0.80 |
| Earnings per share, diluted | 86.00 | 287.00 | -0.69 | -1.53 | -1.61 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 105.9M | 84.7M | 87.6M | 81.6M | 114.9M | 157.6M | 171.2M | 198.3M | 145.3M | 74.3M |
| Receivables | 24.3M | 31.3M | 17.0M | 19.2M | 22.6M | 15.2M | 15.5M | 13.9M | 12.1M | 8.25M |
| Inventory | 54.1M | 45.9M | 37.1M | 38.5M | 29.8M | 20.9M | 18.2M | 13.1M | 11.1M | 7.55M |
| Current assets | 184.3M | 162.0M | 141.7M | 139.3M | 167.3M | 193.8M | 205.0M | 225.3M | 170.1M | 91.8M |
| Property, plant and equipment | 4.42M | 6.26M | 7.75M | 9.25M | 3.36M | 25.6M | 7.78M | 4.74M | 5.10M | 4.74M |
| Goodwill | 0 | 0 | 0 | 5.04M | 5.04M | |||||
| Total assets | 258.5M | 229.7M | 181.0M | 187.8M | 211.8M | 235.3M | 227.2M | 258.0M | 205.2M | 123.0M |
| Accounts payable | 2.45M | 6.55M | 3.71M | 4.44M | 4.97M | 5.81M | 4.61M | 3.30M | 3.55M | 3.52M |
| Current liabilities | 34.1M | 30.1M | 25.3M | 22.0M | 22.6M | 22.6M | 17.0M | 11.4M | 8.29M | 7.42M |
| Long-term debt | 0 | |||||||||
| Total debt | 10.0M | 13.0M | 15.3M | 22.7M | 22.3M | 6.61M | 698.0K | 466.2K | ||
| Total liabilities | 53.6M | 35.6M | 34.4M | 33.6M | 37.0M | 40.7M | 18.9M | 12.1M | 8.75M | 7.42M |
| Shareholders' equity | 205.0M | 194.1M | 146.6M | 154.2M | 174.8M | 194.6M | 208.2M | 245.9M | 196.5M | 115.5M |
| Shares outstanding | 15.4M | 15.8M | 15.4M | 15.4M | 15.4M | 15.4M | 15.4M | 15.4M | 14.0M | 11.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 42.6M | 13.5M | 15.5M | -14.0M | -27.1M | -7.66M | -21.5M | -10.9M | -18.6M | -7.90M |
| Capital spending | -1.21M | -1.38M | -955.0K | -8.64M | -1.02M | -6.47M | -4.04M | -6.15M | -6.91M | -7.11M |
| Free cash flow | 41.4M | 12.1M | 14.5M | -22.6M | -28.1M | -14.1M | -25.5M | -17.0M | -25.5M | -15.0M |
| Cash from investing | -10.8M | -10.9M | -4.88M | -14.7M | -12.8M | -4.57M | -4.04M | -6.15M | -6.91M | -4.48M |
| Cash from financing | -11.1M | -4.95M | -4.60M | -4.33M | -3.12M | -1.51M | -1.58M | 68.8M | 96.5M | 20.4M |
| Dividends paid | -6.17M | 0 | ||||||||
| Share buybacks | 0 | 570.0K | 462.0K | 259.0K | 68.5M | 96.1M | 20.4M | |||
| Change in cash | 20.7M | -2.44M | 5.98M | -32.9M | -43.0M | -13.6M | -27.1M | 51.7M | 71.0M | 8.02M |
Cap table
Built by 6ix from Gentian Diagnostics ASA’s releases
- Common shares
- 15,458,624
- Fully diluted
- 15,458,624
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 15,458,624 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 15,458,624 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Njaal Kind | CFO · Since at least Jul 9, 2026 |
Log in to ask 6ix AI your own questions about Gentian Diagnostics ASA.